TipRanks
Innovent Biologics (DE:6IB)
FRANKFURT:6IB
Germany Market
6IB
Innovent Biologics
RESEARCH TOOLSreports

Innovent Biologics (6IB) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

6IB Analyst Ratings

Strong Buy
19Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6IB Stock 12 Month Forecast

Average Price Target

€15.27
▲(28.84% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is €15.27 with a high forecast of €17.13 and a low forecast of €12.77. The average price target represents a 28.84% change from the last price of €11.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","18":"€18","9.75":"€9.75","12.5":"€12.5","15.25":"€15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.13102736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.267984547368423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.771584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.75,12.5,15.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.796,11.283309796923076,11.770619593846153,12.257929390769231,12.745239187692308,13.232548984615384,13.719858781538461,14.207168578461538,14.694478375384616,15.181788172307693,15.66909796923077,16.156407766153848,16.643717563076923,{"y":17.13102736,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.796,11.139998811336032,11.483997622672064,11.827996434008098,12.17199524534413,12.515994056680162,12.859992868016194,13.203991679352228,13.54799049068826,13.891989302024292,14.235988113360325,14.579986924696357,14.923985736032389,{"y":15.267984547368423,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.796,10.947968,11.099936,11.251904,11.403872,11.55584,11.707808,11.859776,12.011744,12.163712,12.31568,12.467648,12.619616,{"y":12.771584,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.796,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.894,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.824,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.468,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.796,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€17.13Average Price Target€15.27Lowest Price Target€12.77
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:6IB
Unknown Analyst
Bernstein
Not Ranked
Bernstein
€14.6
Buy
23.17%
Upside
Reiterated
09/22/26
Bernstein Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
Citic Securities Analyst forecast on DE:6IB
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€14.25
Buy
20.29%
Upside
Reiterated
09/17/26
Citic Securities Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
DBS Analyst forecast on DE:6IB
Mark Kong CFA
DBS
DBS
€16.42
Buy
38.57%
Upside
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Huatai Securities Analyst forecast on DE:6IB
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
€14.77
Buy
24.66%
Upside
Reiterated
09/12/26
Huatai Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UBS Analyst forecast on DE:6IB
Unknown Analyst
UBS
Not Ranked
UBS
€14.15→€15.43
Buy
30.20%
Upside
Reiterated
09/02/26
UBS Keeps Their Buy Rating on Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on DE:6IB
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
€13.46→€14.71
Buy
24.14%
Upside
Reiterated
09/02/26
BOCOM International Holdings Company Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CSC Financial Analyst forecast on DE:6IB
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
€16.84→€16.92
Buy
42.75%
Upside
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF)
Jefferies Analyst forecast on DE:6IB
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€14.25
Buy
20.29%
Upside
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
Citi Analyst forecast on DE:6IB
Unknown Analyst
Citi
Not Ranked
Citi
€13.11→€17.06
Buy
43.96%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
J.P. Morgan Analyst forecast on DE:6IB
Yang Huang
J.P. Morgan
J.P. Morgan
€13.34→€15.96
Buy
34.72%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on DE:6IB
Jill Wu
CMB International Securities
CMB International Securities
€14.85
Buy
25.34%
Upside
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Bank of America Securities Analyst forecast on DE:6IB
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€15.96
Buy
34.72%
Upside
Reiterated
08/26/26
Bank of America Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CLSA Analyst forecast on DE:6IB
Unknown Analyst
CLSA
Not Ranked
CLSA
€15.95→€16.66
Buy
40.59%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on DE:6IB
Unknown Analyst
Daiwa
Not Ranked
Daiwa
€13.68→€15.39
Buy
29.91%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on DE:6IB
Unknown Analyst
CICC
Not Ranked
CICC
€13.49
Buy
13.84%
Upside
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:6IB
Unknown Analyst
Bernstein
Not Ranked
Bernstein
€14.6
Buy
23.17%
Upside
Reiterated
09/22/26
Bernstein Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
Citic Securities Analyst forecast on DE:6IB
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€14.25
Buy
20.29%
Upside
Reiterated
09/17/26
Citic Securities Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
DBS Analyst forecast on DE:6IB
Mark Kong CFA
DBS
DBS
€16.42
Buy
38.57%
Upside
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Huatai Securities Analyst forecast on DE:6IB
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
€14.77
Buy
24.66%
Upside
Reiterated
09/12/26
Huatai Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UBS Analyst forecast on DE:6IB
Unknown Analyst
UBS
Not Ranked
UBS
€14.15→€15.43
Buy
30.20%
Upside
Reiterated
09/02/26
UBS Keeps Their Buy Rating on Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on DE:6IB
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
€13.46→€14.71
Buy
24.14%
Upside
Reiterated
09/02/26
BOCOM International Holdings Company Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CSC Financial Analyst forecast on DE:6IB
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
€16.84→€16.92
Buy
42.75%
Upside
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF)
Jefferies Analyst forecast on DE:6IB
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€14.25
Buy
20.29%
Upside
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
Citi Analyst forecast on DE:6IB
Unknown Analyst
Citi
Not Ranked
Citi
€13.11→€17.06
Buy
43.96%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
J.P. Morgan Analyst forecast on DE:6IB
Yang Huang
J.P. Morgan
J.P. Morgan
€13.34→€15.96
Buy
34.72%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on DE:6IB
Jill Wu
CMB International Securities
CMB International Securities
€14.85
Buy
25.34%
Upside
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Bank of America Securities Analyst forecast on DE:6IB
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€15.96
Buy
34.72%
Upside
Reiterated
08/26/26
Bank of America Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CLSA Analyst forecast on DE:6IB
Unknown Analyst
CLSA
Not Ranked
CLSA
€15.95→€16.66
Buy
40.59%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on DE:6IB
Unknown Analyst
Daiwa
Not Ranked
Daiwa
€13.68→€15.39
Buy
29.91%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on DE:6IB
Unknown Analyst
CICC
Not Ranked
CICC
€13.49
Buy
13.84%
Upside
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
EHCEncompass Health
MDWDMediwound
OVIDOvid Therapeutics
ARDXArdelyx
STOKStoke Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

3 Months
Jill WuCMB International Securities
Success Rate
8/14 ratings generated profit
57%
Average Return
+10.44%
Copying Jill Wu's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +10.44% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
10/14 ratings generated profit
71%
Average Return
+41.89%
Copying Jill Wu's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +41.89% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
10/14 ratings generated profit
71%
Average Return
+67.98%
Copying Jill Wu's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +67.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6IB Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
11
6
2
0
Buy
8
8
24
27
23
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
19
30
29
23
In the current month, 6IB has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6IB average Analyst price target in the past 3 months is 15.27.
Each month's total comprises the sum of three months' worth of ratings.

6IB Financial Forecast

6IB Earnings Forecast

Next quarter’s earnings estimate for 6IB is €0.15 with a range of €0.15 to €0.15. The previous quarter’s EPS was €0.09. 6IB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6IB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6IB is €0.15 with a range of €0.15 to €0.15. The previous quarter’s EPS was €0.09. 6IB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6IB has Performed in-line its overall industry.

6IB Sales Forecast

Next quarter’s sales forecast for 6IB is €1.33B with a range of €1.21B to €1.45B. The previous quarter’s sales results were €1.10B. 6IB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6IB has Performed in-line its overall industry.
Next quarter’s sales forecast for 6IB is €1.33B with a range of €1.21B to €1.45B. The previous quarter’s sales results were €1.10B. 6IB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6IB has Performed in-line its overall industry.

6IB Stock Forecast FAQ

What is DE:6IB’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is 15.27.
    What is DE:6IB’s upside potential, based on the analysts’ average price target?
    Innovent Biologics has 28.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Innovent Biologics a Buy, Sell or Hold?
          Innovent Biologics has a consensus rating of Strong Buy, which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Innovent Biologics’s share price target?
            The average share price target for Innovent Biologics is 15.27. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €17.13 ,and the lowest forecast is €12.77. The average share price target represents 28.84% Increase from the current price of €11.85.
              What do analysts say about Innovent Biologics?
              Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Innovent Biologics?
                To buy shares of DE:6IB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.